Dong Zhang, Ph.D.

Dr. Zhang’s is the Co-founder and Chief Scientific Officer at D2M Biotherapeutics. Trained as an immunologist, Dr. Zhang has 20 years of drug discovery & development experience in cancer immunotherapy.

Before co-founding D2M, he served as Director, Immuno- Oncology of EMD Serono Research and Development Institute/Merck KGaA. During his 15-year tenure at Merck KGaA, where he progressively shouldered key responsibilities in the Immuno-Oncology pipeline. His significant contributions are highlighted by leading 10 cross-functional Discovery Project teams as Team Leader, with four programs advancing into clinical development, including the marketed Bavencio® (anti- PD-L1, Avelumab®).

Holding a Ph.D. from Chinese Academy of Science, and a B.Sc. in biochemistry from Jilin University, Dr Zhang’s academic prowess is complemented by nine-year post-doc training at Dr. Judy Lieberman’s lab at Harvard Medical School.